首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
Impact of an Educational and Laboratory Stewardship Intervention on Inpatient COVID-19 Therapeutics at a Veterans Affairs Medical Center. 教育和实验室管理干预对退伍军人事务医疗中心住院新冠肺炎治疗的影响。
Pub Date : 2023-05-01 Epub Date: 2023-05-18 DOI: 10.12788/fp.0370
Zane A Conrad, Alonso Pezo Salazar, Austin Akers, Tomasz Z Jodlowski, Li Wang, Henning Drechsler, Donald F Storey, Reuben J Arasaratnam

Background: Accurate and timely prescriptions of COVID-19 therapeutics, laboratory testing, and antimicrobial stewardship have been a challenge throughout the pandemic as new evidence emerges. While universal consultation with infectious disease specialists on patients admitted with COVID-19 is desirable, it is not always feasible due to limited resources.

Observations: In this single-center study, we implemented a combined educational and laboratory stewardship intervention geared toward hospitalist practitioners resulting in improved accuracy of remdesivir and dexamethasone prescriptions, reduced laboratory use of blood cultures, interleukin 6 assay, and Legionella sputum cultures, and a decrease in antibiotic use for patients with mild-to-moderate oxygen requirements over 6 months. These improvements were seen in tandem with decreased reliance on infectious disease consultation.

Conclusions: These efforts support proof of the principle of combined educational and laboratory stewardship interventions to improve the care of COVID-19 patients, especially where infectious disease consultation may not be available or is accessed remotely.

背景:随着新证据的出现,准确及时地开具新冠肺炎治疗药物处方、实验室检测和抗菌药物管理在整个疫情期间一直是一个挑战。虽然与传染病专家就新冠肺炎患者进行普遍咨询是可取的,但由于资源有限,这并不总是可行的。观察结果:在这项单中心研究中,我们针对住院医生实施了教育和实验室管理相结合的干预措施,提高了瑞德西韦和地塞米松处方的准确性,减少了血液培养、白细胞介素6测定和军团菌痰培养的实验室使用,以及6个月以上轻度至中度需氧量患者的抗生素使用减少。这些改善与减少对传染病咨询的依赖同时出现。结论:这些努力有助于证明教育和实验室管理干预相结合的原则,以改善对新冠肺炎患者的护理,特别是在传染病咨询可能不可用或无法远程访问的情况下。
{"title":"Impact of an Educational and Laboratory Stewardship Intervention on Inpatient COVID-19 Therapeutics at a Veterans Affairs Medical Center.","authors":"Zane A Conrad,&nbsp;Alonso Pezo Salazar,&nbsp;Austin Akers,&nbsp;Tomasz Z Jodlowski,&nbsp;Li Wang,&nbsp;Henning Drechsler,&nbsp;Donald F Storey,&nbsp;Reuben J Arasaratnam","doi":"10.12788/fp.0370","DOIUrl":"https://doi.org/10.12788/fp.0370","url":null,"abstract":"<p><strong>Background: </strong>Accurate and timely prescriptions of COVID-19 therapeutics, laboratory testing, and antimicrobial stewardship have been a challenge throughout the pandemic as new evidence emerges. While universal consultation with infectious disease specialists on patients admitted with COVID-19 is desirable, it is not always feasible due to limited resources.</p><p><strong>Observations: </strong>In this single-center study, we implemented a combined educational and laboratory stewardship intervention geared toward hospitalist practitioners resulting in improved accuracy of remdesivir and dexamethasone prescriptions, reduced laboratory use of blood cultures, interleukin 6 assay, and <i>Legionella</i> sputum cultures, and a decrease in antibiotic use for patients with mild-to-moderate oxygen requirements over 6 months. These improvements were seen in tandem with decreased reliance on infectious disease consultation.</p><p><strong>Conclusions: </strong>These efforts support proof of the principle of combined educational and laboratory stewardship interventions to improve the care of COVID-19 patients, especially where infectious disease consultation may not be available or is accessed remotely.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 5","pages":"146-151"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506492/pdf/fp-40-05-146.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Battlefield Acupuncture vs Ketorolac for Treating Pain in the Emergency Department. 战地针灸与酮罗拉酸在急诊科治疗疼痛的比较
Eva Galka, Zane Elfessi, Tulika Singh, Erica Liu, Caitlin Turnbull

Background: Many patients arrive in the emergency department (ED) with acute pain. Battlefield acupuncture (BFA) uses small, semipermanent acupuncture needles in 5 set points anatomically located on each ear to reduce pain in a few minutes. Pain relief can last months, depending on the pathology of the pain. At the Jesse Brown Veterans Affairs Medical Center (JBVAMC) ED, ketorolac 15 mg is the preferred first-line treatment of acute, noncancer pain. In 2018, BFA was offered first to veterans presenting with acute or acute-on-chronic pain to the ED; however, its effectiveness in pain reduction vs ketorolac has not been evaluated in this patient population. The objective of this study was to determine whether BFA monotherapy was noninferior to ketorolac 15 mg for reducing pain scores in the ED.

Methods: This study was a retrospective, electronic chart review of patients who presented to JBVAMC ED with acute pain or acute-on-chronic pain and received ketorolac or BFA. The primary endpoint was the mean difference in the numeric rating scale (NRS) pain score from baseline. Secondary endpoints included the number of patients receiving pain medications, including topical analgesics, at discharge and treatment-related adverse events in the ED.

Results: A total of 61 patients were included in the study. Baseline characteristics were similar between the 2 groups except for the average baseline NRS pain score, which was higher in the BFA group (8.7 vs 7.7; P = .02). The mean difference in NRS pain scores from baseline to post-intervention was 3.9 for the BFA group and 5.1 for the ketorolac group. The difference in reducing the NRS pain score between the intervention groups was not statistically significant. No adverse events were observed in either treatment group.

Conclusions: For treating acute and acute-on-chronic pain in the ED, BFA did not differ compared with ketorolac 15 mg in NRS pain score reduction. This study's results add to the limited existing literature suggesting that both interventions could result in clinically significant reductions in pain scores for patients presenting to the ED with severe and very severe pain, indicating BFA could be a viable nonpharmacologic treatment option.

背景:许多患者来到急诊科(ED)急性疼痛。战地针灸(BFA)使用小的、半永久性的针灸针,在每只耳朵上的5个解剖学上的穴位上,在几分钟内减轻疼痛。疼痛的缓解可以持续数月,这取决于疼痛的病理。在杰西布朗退伍军人事务医疗中心(JBVAMC) ED, 15毫克酮洛酸是首选的一线治疗急性,非癌性疼痛。2018年,BFA首先提供给急诊科出现急性或急性慢性疼痛的退伍军人;然而,与酮罗拉酸相比,其减轻疼痛的有效性尚未在该患者群体中进行评估。本研究的目的是确定BFA单药治疗在降低ED疼痛评分方面是否优于酮洛拉酸15mg。方法:本研究是一项回顾性的电子图表回顾,这些患者在JBVAMC ED就诊时伴有急性疼痛或急性慢性疼痛,并接受了酮洛拉酸或BFA治疗。主要终点是数值评定量表(NRS)疼痛评分与基线的平均差异。次要终点包括出院时接受止痛药(包括局部镇痛药)的患者数量和ed中与治疗相关的不良事件。结果:共有61名患者纳入研究。两组之间的基线特征相似,除了平均基线NRS疼痛评分,BFA组更高(8.7 vs 7.7;P = .02)。从基线到干预后NRS疼痛评分的平均差异BFA组为3.9,酮罗拉酸组为5.1。干预组间NRS疼痛评分降低差异无统计学意义。两组均未见不良事件发生。结论:对于治疗急症患者的急性和急性伴慢性疼痛,BFA与酮洛拉酸15mg在NRS疼痛评分降低方面没有差异。本研究的结果补充了有限的现有文献,表明这两种干预措施都可以显著降低患有严重和非常严重疼痛的ED患者的疼痛评分,表明BFA可能是一种可行的非药物治疗选择。
{"title":"Battlefield Acupuncture vs Ketorolac for Treating Pain in the Emergency Department.","authors":"Eva Galka,&nbsp;Zane Elfessi,&nbsp;Tulika Singh,&nbsp;Erica Liu,&nbsp;Caitlin Turnbull","doi":"10.12788/fp.0369","DOIUrl":"https://doi.org/10.12788/fp.0369","url":null,"abstract":"<p><strong>Background: </strong>Many patients arrive in the emergency department (ED) with acute pain. Battlefield acupuncture (BFA) uses small, semipermanent acupuncture needles in 5 set points anatomically located on each ear to reduce pain in a few minutes. Pain relief can last months, depending on the pathology of the pain. At the Jesse Brown Veterans Affairs Medical Center (JBVAMC) ED, ketorolac 15 mg is the preferred first-line treatment of acute, noncancer pain. In 2018, BFA was offered first to veterans presenting with acute or acute-on-chronic pain to the ED; however, its effectiveness in pain reduction vs ketorolac has not been evaluated in this patient population. The objective of this study was to determine whether BFA monotherapy was noninferior to ketorolac 15 mg for reducing pain scores in the ED.</p><p><strong>Methods: </strong>This study was a retrospective, electronic chart review of patients who presented to JBVAMC ED with acute pain or acute-on-chronic pain and received ketorolac or BFA. The primary endpoint was the mean difference in the numeric rating scale (NRS) pain score from baseline. Secondary endpoints included the number of patients receiving pain medications, including topical analgesics, at discharge and treatment-related adverse events in the ED.</p><p><strong>Results: </strong>A total of 61 patients were included in the study. Baseline characteristics were similar between the 2 groups except for the average baseline NRS pain score, which was higher in the BFA group (8.7 vs 7.7; <i>P</i> = .02). The mean difference in NRS pain scores from baseline to post-intervention was 3.9 for the BFA group and 5.1 for the ketorolac group. The difference in reducing the NRS pain score between the intervention groups was not statistically significant. No adverse events were observed in either treatment group.</p><p><strong>Conclusions: </strong>For treating acute and acute-on-chronic pain in the ED, BFA did not differ compared with ketorolac 15 mg in NRS pain score reduction. This study's results add to the limited existing literature suggesting that both interventions could result in clinically significant reductions in pain scores for patients presenting to the ED with severe and very severe pain, indicating BFA could be a viable nonpharmacologic treatment option.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 4","pages":"110-115"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202138/pdf/fp-40-04-110.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VA-Based Peritoneal Dialysis Program Feasibility Considerations and Process Outline. 退伍军人腹膜透析计划的可行性考虑因素和流程概要。
Pub Date : 2023-04-01 Epub Date: 2023-04-15 DOI: 10.12788/fp.0356
Anuradha Wadhwa, Linda F Fried, Kerri Cavanaugh, Karen MacKichan, Arjun D Sinha, Sarah Adam, Laurie Hippensteel, Scott Ruele, Susan T Crowley, Ashutosh M Shukla

Background: Home dialysis utilization is lower among veterans than in the general US population. Several sociodemographic factors and comorbidities contribute to peritoneal dialysis (PD) underutilization. In 2019, the Veterans Health Administration (VHA) Kidney Disease Program Office convened a PD workgroup to address this concern.

Observations: The PD workgroup was explicitly concerned by the limited availability of PD within the VHA, which frequently requires veterans to transition kidney disease care from US Department of Veterans Affairs medical centers (VAMCs) to non-VHA facilities when they progress from chronic kidney disease to end-stage kidney disease, causing fragmentation of care. Since the administrative requirements and infrastructure of VAMCs vary, the workgroup focused its deliberations on synthesizing a standard process for evaluating the feasibility and establishing a new PD program within any individual VAMC. A 3-phased approach was envisioned, beginning with ascertainment of prerequisites, leading to an examination of the clinical and financial feasibility through the process of data gathering and synthesis, culminating in a business plan that translates the previous 2 steps into an administrative document necessary for obtaining VHA approvals.

Conclusions: VAMCs can use the guide presented here to improve therapeutic options for veterans with kidney failure by establishing a new or restructured PD program.

背景:退伍军人的家庭透析使用率低于美国普通人群。一些社会人口因素和合并症导致腹膜透析(PD)利用率不足。2019 年,退伍军人健康管理局(VHA)肾脏病项目办公室召集了一个腹膜透析工作组来解决这一问题:当退伍军人从慢性肾脏病发展到终末期肾脏病时,退伍军人健康管理局经常要求退伍军人将肾脏病护理从美国退伍军人事务部医疗中心(VAMC)转到非退伍军人健康管理局设施,造成护理分散,因此,肾脏病项目工作组明确关注退伍军人健康管理局内肾脏病透析的有限可用性。由于退伍军人医疗中心的行政要求和基础设施各不相同,工作组的讨论重点是总结出一套标准流程,用于评估可行性并在任何一家退伍军人医疗中心内建立新的肾脏病治疗项目。工作小组设想了一个分三阶段的方法,首先是确定先决条件,然后通过数据收集和综合过程对临床和财务可行性进行审查,最后制定一份业务计划,将前两个步骤转化为获得退伍军人医疗管理局批准所需的行政文件:退伍军人医疗管理中心可以利用本文介绍的指南,通过建立新的或重组的肾功能衰竭计划来改善退伍军人肾功能衰竭的治疗方案。
{"title":"VA-Based Peritoneal Dialysis Program Feasibility Considerations and Process Outline.","authors":"Anuradha Wadhwa, Linda F Fried, Kerri Cavanaugh, Karen MacKichan, Arjun D Sinha, Sarah Adam, Laurie Hippensteel, Scott Ruele, Susan T Crowley, Ashutosh M Shukla","doi":"10.12788/fp.0356","DOIUrl":"10.12788/fp.0356","url":null,"abstract":"<p><strong>Background: </strong>Home dialysis utilization is lower among veterans than in the general US population. Several sociodemographic factors and comorbidities contribute to peritoneal dialysis (PD) underutilization. In 2019, the Veterans Health Administration (VHA) Kidney Disease Program Office convened a PD workgroup to address this concern.</p><p><strong>Observations: </strong>The PD workgroup was explicitly concerned by the limited availability of PD within the VHA, which frequently requires veterans to transition kidney disease care from US Department of Veterans Affairs medical centers (VAMCs) to non-VHA facilities when they progress from chronic kidney disease to end-stage kidney disease, causing fragmentation of care. Since the administrative requirements and infrastructure of VAMCs vary, the workgroup focused its deliberations on synthesizing a standard process for evaluating the feasibility and establishing a new PD program within any individual VAMC. A 3-phased approach was envisioned, beginning with ascertainment of prerequisites, leading to an examination of the clinical and financial feasibility through the process of data gathering and synthesis, culminating in a business plan that translates the previous 2 steps into an administrative document necessary for obtaining VHA approvals.</p><p><strong>Conclusions: </strong>VAMCs can use the guide presented here to improve therapeutic options for veterans with kidney failure by establishing a new or restructured PD program.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 4","pages":"116-122b"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202139/pdf/fp-40-04-116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9516269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Gabapentin and Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome. 加巴喷丁联合巴氯芬治疗住院患者酒精戒断综合征的疗效评价。
Kristina Karapetyan, Zachary Rosenfeldt, Kaylee Caniff

Background: Benzodiazepines are considered the gold standard for treatment of alcohol withdrawal syndrome (AWS), a group of symptoms that occur after abrupt cessation of alcohol use, but may be associated with serious adverse effects. Given the safety concerns, alternative treatment options for AWS management have been investigated, including gabapentin and baclofen. Because no available studies have investigated the inpatient use of the gabapentin and baclofen combination for alcohol detoxification, this study aims to evaluate their efficacy and safety in the inpatient hospital setting.

Methods: This retrospective cohort study at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, included patients who were aged ≥ 18 years and who were admitted to the general acute medicine floor for the primary indication of AWS from January 1, 2014, to July 31, 2021. The primary outcome was the length of stay, defined as hours from admission to either discharge or 36 hours with a Clinical Institute Withdrawal Assessment of Alcohol (CIWA) score ≤ 8. Electronic health records were reviewed to collect CIWA scores, alcohol withdrawal seizure and delirium tremens incidence, rates of conversions from gabapentin/baclofen to lorazepam, rates of transitions to a higher level of care, and readmission for AWS within 30 days.

Results: Mean length of stay in the gabapentin/baclofen group was statistically significantly shorter compared with the benzodiazepine group (42.6 vs 82.5 hours, P < .001). The study found no significant difference between the gabapentin/baclofen and benzodiazepine groups in AWS readmission, adjuvant medications for AWS management, and number of patients who transitioned to a higher level of care. Overall, the safety of gabapentin/baclofen vs benzodiazepine were comparable; however, 1 patient experienced a seizure, and 1 patient experienced delirium tremens during admission in the benzodiazepine group.

Conclusions: Gabapentin/baclofen combination seems to be an effective and safe alternative to benzodiazepines and may be considered for managing mild AWS in hospitalized patients, but additional research is needed to examine this regimen.

背景:苯二氮卓类药物被认为是治疗酒精戒断综合征(AWS)的金标准,这是一组在突然停止使用酒精后出现的症状,但可能与严重的不良反应有关。考虑到安全性问题,已经研究了替代治疗方案,包括加巴喷丁和巴氯芬。由于目前尚无研究调查住院患者使用加巴喷丁和巴氯芬联合治疗酒精解毒,本研究旨在评估其在住院医院环境中的有效性和安全性。方法:这项回顾性队列研究在伊利诺伊州北芝加哥的James A. Lovell上尉联邦卫生保健中心进行,纳入了2014年1月1日至2021年7月31日期间因主要适应证AWS而入住普通急性医学病房的年龄≥18岁的患者。主要终点是住院时间,定义为从入院到出院的小时数或临床研究所酒精戒断评估(CIWA)评分≤8的36小时。回顾电子健康记录,收集CIWA评分、酒精戒断性发作和震颤性谵妄发生率、从加巴喷丁/巴氯芬到劳拉西泮的转换率、过渡到更高级别护理的比率以及30天内AWS的再入院率。结果:加巴喷丁/巴氯芬组的平均住院时间较苯二氮卓组有统计学意义(42.6 h vs 82.5 h, P < 0.001)。研究发现加巴喷丁/巴氯芬组和苯二氮卓组在AWS再入院、AWS管理的辅助用药以及转移到更高级别护理的患者数量方面没有显著差异。总体而言,加巴喷丁/巴氯芬与苯二氮卓的安全性相当;然而,在入院期间,苯二氮卓组有1例患者发生癫痫发作,1例患者发生震颤谵妄。结论:加巴喷丁/巴氯芬联合用药似乎是苯二氮卓类药物的一种有效和安全的替代方案,可以考虑用于治疗住院患者的轻度AWS,但需要进一步的研究来检验该方案。
{"title":"Evaluation of Gabapentin and Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome.","authors":"Kristina Karapetyan,&nbsp;Zachary Rosenfeldt,&nbsp;Kaylee Caniff","doi":"10.12788/fp.0362","DOIUrl":"https://doi.org/10.12788/fp.0362","url":null,"abstract":"<p><strong>Background: </strong>Benzodiazepines are considered the gold standard for treatment of alcohol withdrawal syndrome (AWS), a group of symptoms that occur after abrupt cessation of alcohol use, but may be associated with serious adverse effects. Given the safety concerns, alternative treatment options for AWS management have been investigated, including gabapentin and baclofen. Because no available studies have investigated the inpatient use of the gabapentin and baclofen combination for alcohol detoxification, this study aims to evaluate their efficacy and safety in the inpatient hospital setting.</p><p><strong>Methods: </strong>This retrospective cohort study at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, included patients who were aged ≥ 18 years and who were admitted to the general acute medicine floor for the primary indication of AWS from January 1, 2014, to July 31, 2021. The primary outcome was the length of stay, defined as hours from admission to either discharge or 36 hours with a Clinical Institute Withdrawal Assessment of Alcohol (CIWA) score ≤ 8. Electronic health records were reviewed to collect CIWA scores, alcohol withdrawal seizure and delirium tremens incidence, rates of conversions from gabapentin/baclofen to lorazepam, rates of transitions to a higher level of care, and readmission for AWS within 30 days.</p><p><strong>Results: </strong>Mean length of stay in the gabapentin/baclofen group was statistically significantly shorter compared with the benzodiazepine group (42.6 vs 82.5 hours, <i>P</i> < .001). The study found no significant difference between the gabapentin/baclofen and benzodiazepine groups in AWS readmission, adjuvant medications for AWS management, and number of patients who transitioned to a higher level of care. Overall, the safety of gabapentin/baclofen vs benzodiazepine were comparable; however, 1 patient experienced a seizure, and 1 patient experienced delirium tremens during admission in the benzodiazepine group.</p><p><strong>Conclusions: </strong>Gabapentin/baclofen combination seems to be an effective and safe alternative to benzodiazepines and may be considered for managing mild AWS in hospitalized patients, but additional research is needed to examine this regimen.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 4","pages":"128-133"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202137/pdf/fp-40-04-128.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Grade Staphylococcus lugdunensis Bacteremia in a Patient on Home Hemodialysis. 1例家庭血液透析患者的高级别葡萄球菌菌血症。
Ashley K Saito, Simon Wu

Background: Staphylococcus lugdunensis (S lugdunensis) is a species of coagulase-negative Staphylococcus and a constituent of human skin flora. S lugdunensis has gained notoriety for its virulence, which resembles Staphylococcus aureus (S aureus). S lugdunensis is now recognized as an important nosocomial pathogen and cause of prosthetic device infections, including vascular catheter infections.

Case presentation: A 60-year-old man with a history of uncontrolled type 2 diabetes mellitus and end-stage renal disease on home hemodialysis via arteriovenous fistula (AVF) presented to the emergency department for evaluation of subacute progressive low back pain. Initial laboratory tests were notable for elevated inflammatory markers. Magnetic resonance imaging with contrast of the thoracic and lumbar spine revealed abnormal marrow edema in the T11-T12 vertebrae with abnormal fluid signal in the T11-T12 disc space. Cultures grew methicillin-sensitive S lugdunensis. The patient's antibiotic regimen was narrowed to IV oxacillin. He was transitioned to IV cefazolin dosed 3 times weekly after hemodialysis and an outpatient dialysis center.

Conclusions: Treatment of bacteremia caused by S lugdunensis or S aureus should be managed with prompt initiation of IV antistaphylococcal therapy, a thorough evaluation for the source of bacteremia as well as metastatic complications, and consultation with an infectious disease specialist. This case highlights AVF as a potential source for infection even without localized signs of infection. The buttonhole method of AVF cannulation was thought to be a major contributor to the development and persistence of our patient's bacteremia. This risk should be discussed with patients using a shared decision-making approach when developing a dialysis treatment plan.

背景:lugdunensis葡萄球菌(S lugdunensis)是一种凝固酶阴性葡萄球菌,是人类皮肤菌群的组成部分。lugdunensis因其类似金黄色葡萄球菌(S aureus)的毒力而臭名昭著。lugdunensis目前被认为是一种重要的医院病原体,也是导致假体装置感染(包括血管导管感染)的原因。病例介绍:一名60岁男性,有2型糖尿病和终末期肾病史,通过动静脉瘘(AVF)进行家庭血液透析,被送到急诊科评估亚急性进行性腰痛。最初的实验室检查显示炎症标志物升高。胸椎和腰椎磁共振造影显示T11-T12椎体异常骨髓水肿,T11-T12椎间盘间隙异常液体信号。培养出对甲氧西林敏感的S lugdunensis。患者的抗生素治疗方案缩小到静脉注射奥西林。他在血液透析和门诊透析中心后转为静脉注射头孢唑林,每周给药3次。结论:由lugdunensis或金黄色葡萄球菌引起的菌血症的治疗应及时开始静脉注射抗葡萄球菌治疗,对菌血症的来源和转移性并发症进行彻底评估,并咨询传染病专家。本病例突出表明,即使没有局部感染迹象,AVF也是潜在的感染源。AVF插管的扣眼方法被认为是我们患者菌血症发生和持续的主要原因。在制定透析治疗计划时,应与患者讨论这种风险,并采用共同决策的方法。
{"title":"High-Grade <i>Staphylococcus lugdunensis</i> Bacteremia in a Patient on Home Hemodialysis.","authors":"Ashley K Saito,&nbsp;Simon Wu","doi":"10.12788/fp.0361","DOIUrl":"https://doi.org/10.12788/fp.0361","url":null,"abstract":"<p><strong>Background: </strong><i>Staphylococcus lugdunensis (S lugdunensis)</i> is a species of coagulase-negative <i>Staphylococcus</i> and a constituent of human skin flora. <i>S lugdunensis</i> has gained notoriety for its virulence, which resembles <i>Staphylococcus aureus (S aureus)</i>. <i>S lugdunensis</i> is now recognized as an important nosocomial pathogen and cause of prosthetic device infections, including vascular catheter infections.</p><p><strong>Case presentation: </strong>A 60-year-old man with a history of uncontrolled type 2 diabetes mellitus and end-stage renal disease on home hemodialysis via arteriovenous fistula (AVF) presented to the emergency department for evaluation of subacute progressive low back pain. Initial laboratory tests were notable for elevated inflammatory markers. Magnetic resonance imaging with contrast of the thoracic and lumbar spine revealed abnormal marrow edema in the T11-T12 vertebrae with abnormal fluid signal in the T11-T12 disc space. Cultures grew methicillin-sensitive <i>S lugdunensis</i>. The patient's antibiotic regimen was narrowed to IV oxacillin. He was transitioned to IV cefazolin dosed 3 times weekly after hemodialysis and an outpatient dialysis center.</p><p><strong>Conclusions: </strong>Treatment of bacteremia caused by <i>S lugdunensis</i> or <i>S aureus</i> should be managed with prompt initiation of IV antistaphylococcal therapy, a thorough evaluation for the source of bacteremia as well as metastatic complications, and consultation with an infectious disease specialist. This case highlights AVF as a potential source for infection even without localized signs of infection. The buttonhole method of AVF cannulation was thought to be a major contributor to the development and persistence of our patient's bacteremia. This risk should be discussed with patients using a shared decision-making approach when developing a dialysis treatment plan.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 4","pages":"123-127"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202140/pdf/fp-40-04-123.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9518983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to Evidence-Based Outpatient Antimicrobial Prescribing Guidelines at a Tribal Health System. 部落卫生系统对循证门诊抗菌药物处方指南的依从性。
Kayla Rose, Mary C Byrne

Background: In 2019, the Tuba City Regional Health Care Corporation on the Navajo Reservation in northeastern Arizona established facility-wide, evidence-based outpatient antimicrobial guidelines. We aimed to evaluate adherence to these guidelines.

Methods: A retrospective chart review of the electronic health record for all ages was conducted from August 1, 2020, to August 1, 2021, to evaluate antimicrobials prescribed for indications covered by the facility prescribing guidelines. The appropriateness of the antimicrobial prescribed was assessed and reported as a percentage. An educational intervention and a survey were then distributed from March 2, 2022, to March 31, 2022, to all prescribers.

Results: Overall adherence to prescribing guidelines over the period assessed was 86%, 4% short of the study goal of 90%. Before the educational intervention, 61.5% of prescribers used the prescribing guidelines to guide their antibiotic choice, while after the educational intervention, 87.1% of prescribers indicated a willingness to use the guidelines to guide their antibiotic choice.

Conclusions: Adherence to the facility guidelines was already high at 86%. Educational interventions were performed but their efficacy could not be assessed within the time constraints of the study.

背景:2019年,位于亚利桑那州东北部纳瓦霍保留地的图巴市地区医疗保健公司建立了全设施范围内的循证门诊抗菌指南。我们的目的是评估这些指南的遵守情况。方法:从2020年8月1日至2021年8月1日,对所有年龄段的电子健康记录进行回顾性图表审查,以评估医院处方指南涵盖的适应症所开的抗菌素。对抗菌药物处方的适宜性进行评估并按百分比报告。然后在2022年3月2日至3月31日向所有处方者分发教育干预和调查。结果:在评估期间,处方指南的总体依从性为86%,比90%的研究目标低4%。教育干预前,61.5%的开处方者使用处方指南指导其选择抗生素,教育干预后,87.1%的开处方者表示愿意使用指南指导其选择抗生素。结论:医院指南的依从性已经高达86%。进行了教育干预,但在研究的时间限制内无法评估其效果。
{"title":"Adherence to Evidence-Based Outpatient Antimicrobial Prescribing Guidelines at a Tribal Health System.","authors":"Kayla Rose,&nbsp;Mary C Byrne","doi":"10.12788/fp.0363","DOIUrl":"https://doi.org/10.12788/fp.0363","url":null,"abstract":"<p><strong>Background: </strong>In 2019, the Tuba City Regional Health Care Corporation on the Navajo Reservation in northeastern Arizona established facility-wide, evidence-based outpatient antimicrobial guidelines. We aimed to evaluate adherence to these guidelines.</p><p><strong>Methods: </strong>A retrospective chart review of the electronic health record for all ages was conducted from August 1, 2020, to August 1, 2021, to evaluate antimicrobials prescribed for indications covered by the facility prescribing guidelines. The appropriateness of the antimicrobial prescribed was assessed and reported as a percentage. An educational intervention and a survey were then distributed from March 2, 2022, to March 31, 2022, to all prescribers.</p><p><strong>Results: </strong>Overall adherence to prescribing guidelines over the period assessed was 86%, 4% short of the study goal of 90%. Before the educational intervention, 61.5% of prescribers used the prescribing guidelines to guide their antibiotic choice, while after the educational intervention, 87.1% of prescribers indicated a willingness to use the guidelines to guide their antibiotic choice.</p><p><strong>Conclusions: </strong>Adherence to the facility guidelines was already high at 86%. Educational interventions were performed but their efficacy could not be assessed within the time constraints of the study.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"87-89"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204931/pdf/fp-40-03-87.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9527774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Augmented Reality Demonstration Survey Results From a Veteran Affairs Medical Center. 来自退伍军人医疗中心的增强现实演示调查结果。
Thomas F Osborne, David M Arreola, Zachary P Veigulis, Christopher Morley, Osamah Choudhry, Wenbo Lan, Kristopher R Teague, Ryan Vega, Satish M Mahajan

Background: Augmented reality (AR) has a wide range of potential applications to enhance health care. Understanding how the introduction of a new technology may impact employees is essential for overall health care system success.

Methods: Survey responses were obtained before and after a health care-focused interactive AR demonstration at a US Department of Veterans Affairs (VA) medical center. Data were assessed with descriptive statistics, Wilcoxon signed rank matched pairs test, pooled t test, and analysis of variance.

Results: A total of 166 individuals participated in the demonstration and survey. Statistically significant improvements were seen after the use of the new AR technology in each of the categories assessed using a 5-point Likert scale. Scores for perceptions of institutional innovativeness increased from 3.4 to 4.5 (a 22% increase; P < .001); employee excitement about the VA increased from 3.7 to 4.3 (a 12% increase; P < .001); and employee likelihood to continue working at VA increased from 4.2 to 4.5 (a 6% increase; P < .001). Subgroup analysis demonstrated statistically significant differences by employee veteran status, VA tenure, and sex. Respondents felt strongly that this type of work will positively impact health care and that the VA should continue these efforts.

Conclusions: An AR demonstration significantly increased employee excitement and intention to continue employment at the VA and provided valuable insights about the most impactful uses of AR in health care.

背景:增强现实(AR)在增强医疗保健方面具有广泛的潜在应用。了解新技术的引入对员工的影响对于整个医疗保健系统的成功至关重要。方法:在美国退伍军人事务部(VA)医疗中心进行以医疗保健为重点的交互式AR演示前后获得调查反馈。资料采用描述性统计、Wilcoxon符号秩匹配对检验、合并t检验和方差分析进行评估。结果:共166人参与了示范和调查。在使用5分李克特量表评估的每个类别中,使用新的AR技术后,统计上都有显着的改善。对制度创新的认知得分从3.4上升到4.5(上升22%;P < 0.001);员工对VA的兴奋度从3.7上升到4.3(增长了12%;P < 0.001);员工继续在VA工作的可能性从4.2增加到4.5(增加了6%;P < 0.001)。亚组分析显示,雇员的退伍军人身份、VA任期和性别在统计上存在显著差异。受访者强烈认为,这类工作将对医疗保健产生积极影响,退伍军人事务部应继续努力。结论:AR演示显著增加了员工的兴奋感和继续在VA工作的意愿,并提供了关于AR在医疗保健中最有效使用的有价值的见解。
{"title":"Augmented Reality Demonstration Survey Results From a Veteran Affairs Medical Center.","authors":"Thomas F Osborne,&nbsp;David M Arreola,&nbsp;Zachary P Veigulis,&nbsp;Christopher Morley,&nbsp;Osamah Choudhry,&nbsp;Wenbo Lan,&nbsp;Kristopher R Teague,&nbsp;Ryan Vega,&nbsp;Satish M Mahajan","doi":"10.12788/fp.0364","DOIUrl":"https://doi.org/10.12788/fp.0364","url":null,"abstract":"<p><strong>Background: </strong>Augmented reality (AR) has a wide range of potential applications to enhance health care. Understanding how the introduction of a new technology may impact employees is essential for overall health care system success.</p><p><strong>Methods: </strong>Survey responses were obtained before and after a health care-focused interactive AR demonstration at a US Department of Veterans Affairs (VA) medical center. Data were assessed with descriptive statistics, Wilcoxon signed rank matched pairs test, pooled <i>t</i> test, and analysis of variance.</p><p><strong>Results: </strong>A total of 166 individuals participated in the demonstration and survey. Statistically significant improvements were seen after the use of the new AR technology in each of the categories assessed using a 5-point Likert scale. Scores for perceptions of institutional innovativeness increased from 3.4 to 4.5 (a 22% increase; <i>P</i> < .001); employee excitement about the VA increased from 3.7 to 4.3 (a 12% increase; <i>P</i> < .001); and employee likelihood to continue working at VA increased from 4.2 to 4.5 (a 6% increase; <i>P</i> < .001). Subgroup analysis demonstrated statistically significant differences by employee veteran status, VA tenure, and sex. Respondents felt strongly that this type of work will positively impact health care and that the VA should continue these efforts.</p><p><strong>Conclusions: </strong>An AR demonstration significantly increased employee excitement and intention to continue employment at the VA and provided valuable insights about the most impactful uses of AR in health care.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"90-97"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204933/pdf/fp-40-03-90.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9578672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No Wrong Floor on the Elevator: A Vision for the VA as an Age-Friendly Health System. 电梯上没有错的楼层:退伍军人事务部作为一个老年人友好的健康系统的愿景。
Andrea Wershof Schwartz

Background: The Age-Friendly Health Systems Initiative is a quality improvement movement led by the Institute for Healthcare Improvement and supported by the John A. Hartford Foundation to improve care for older adults. The US Department of Veterans Affairs (VA) has set a goal to become the largest integrated Age-Friendly Health System in the United States.

Observations: As the veteran population ages, delivering Age-Friendly care is an urgent priority. VA clinicians should apply the 4Ms of the Age-Friendly Health Systems Initiative: Mobility, Mentation, Medications, and What Matters.

Conclusions: No matter which floor a veteran exits on a VA elevator, they should expect to receive Age-Friendly care that will meet their needs as they age.

背景:老年人友好型卫生系统倡议是一项质量改进运动,由卫生保健改进研究所领导,由约翰·哈特福德基金会支持,旨在改善老年人的护理。美国退伍军人事务部(VA)设定了一个目标,要成为美国最大的老年人友好型综合医疗系统。观察:随着老年人口的老龄化,提供老年友好型护理是当务之急。退伍军人管理局的临床医生应该应用老年友好型卫生系统倡议中的4Ms:行动能力、精神状态、药物治疗和重要事项。结论:无论退伍军人从退伍军人事务部电梯的哪一层出口,他们都应该期待得到老年人友好型护理,以满足他们随着年龄增长的需求。
{"title":"No Wrong Floor on the Elevator: A Vision for the VA as an Age-Friendly Health System.","authors":"Andrea Wershof Schwartz","doi":"10.12788/fp.0368","DOIUrl":"https://doi.org/10.12788/fp.0368","url":null,"abstract":"<p><strong>Background: </strong>The Age-Friendly Health Systems Initiative is a quality improvement movement led by the Institute for Healthcare Improvement and supported by the John A. Hartford Foundation to improve care for older adults. The US Department of Veterans Affairs (VA) has set a goal to become the largest integrated Age-Friendly Health System in the United States.</p><p><strong>Observations: </strong>As the veteran population ages, delivering Age-Friendly care is an urgent priority. VA clinicians should apply the 4Ms of the Age-Friendly Health Systems Initiative: Mobility, Mentation, Medications, and What Matters.</p><p><strong>Conclusions: </strong>No matter which floor a veteran exits on a VA elevator, they should expect to receive Age-Friendly care that will meet their needs as they age.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"98-100"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204932/pdf/fp-40-03-98.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9578680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Acetaminophen as Renoprotective Treatment in a Patient With Severe Malaria. 对乙酰氨基酚对重症疟疾患者肾保护作用的研究。
Joshua Shultz, Marina Antar-Shultz, Jorge Antonio Lamarche, Panagiotis Zervogiannis, Mohamed Taha

Background: Severe falciparum malaria with renal impairment carries a significant risk of poor outcomes, including death. Previous randomized controlled trials using acetaminophen as adjunctive treatment for malaria-associated renal failure have demonstrated improvements in renal function and kidney injury progression.

Case presentation: A 50-year-old man with severe falciparum malaria presented with hemolytic anemia, oliguric acute kidney injury, nephrotic range proteinuria, and significant architectural changes on renal ultrasound. Treatment with oral acetaminophen 975 mg every 6 hours was based on the randomized controlled trial protocol to salvage his renal function and avoid dialysis. During the acetaminophen course, urine output and cystatin C level improved with only mild, asymptomatic elevations in aminotransferases that were corrected on follow-up. The patient recovered without requiring dialysis.

Conclusions: Acetaminophen's potential to mitigate the oxidative damage of hemoproteins suggests its use as a treatment in severe malaria with renal impairment.

背景:伴有肾脏损害的严重恶性疟疾具有显著的不良预后风险,包括死亡。先前的随机对照试验使用对乙酰氨基酚作为疟疾相关性肾衰竭的辅助治疗,已经证明了肾功能和肾损伤进展的改善。病例介绍:一名50岁男性重症恶性疟疾患者,表现为溶血性贫血,少尿急性肾损伤,肾病范围蛋白尿,肾脏超声检查有明显的结构改变。根据随机对照试验方案,每6小时口服对乙酰氨基酚975 mg,以挽救其肾功能并避免透析。在对乙酰氨基酚治疗过程中,尿量和胱抑素C水平有所改善,只有轻微的、无症状的转氨酶升高,在随访中得到纠正。病人不需要透析就康复了。结论:对乙酰氨基酚减轻血红蛋白氧化损伤的潜力表明其可用于治疗严重疟疾伴肾损害。
{"title":"Acetaminophen as Renoprotective Treatment in a Patient With Severe Malaria.","authors":"Joshua Shultz,&nbsp;Marina Antar-Shultz,&nbsp;Jorge Antonio Lamarche,&nbsp;Panagiotis Zervogiannis,&nbsp;Mohamed Taha","doi":"10.12788/fp.0355","DOIUrl":"https://doi.org/10.12788/fp.0355","url":null,"abstract":"<p><strong>Background: </strong>Severe falciparum malaria with renal impairment carries a significant risk of poor outcomes, including death. Previous randomized controlled trials using acetaminophen as adjunctive treatment for malaria-associated renal failure have demonstrated improvements in renal function and kidney injury progression.</p><p><strong>Case presentation: </strong>A 50-year-old man with severe falciparum malaria presented with hemolytic anemia, oliguric acute kidney injury, nephrotic range proteinuria, and significant architectural changes on renal ultrasound. Treatment with oral acetaminophen 975 mg every 6 hours was based on the randomized controlled trial protocol to salvage his renal function and avoid dialysis. During the acetaminophen course, urine output and cystatin C level improved with only mild, asymptomatic elevations in aminotransferases that were corrected on follow-up. The patient recovered without requiring dialysis.</p><p><strong>Conclusions: </strong>Acetaminophen's potential to mitigate the oxidative damage of hemoproteins suggests its use as a treatment in severe malaria with renal impairment.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204929/pdf/fp-40-03-e0355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9578679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central Sleep Apnea in Adults: Diagnosis and Treatment. 成人中枢性睡眠呼吸暂停:诊断和治疗。
Dara D Regn, Anh H Davis, William D Smith, Catherine J Blasser, Caelan M Ford

Background: While the literature has demonstrated a higher prevalence of moderate-to-severe obstructive sleep apnea (OSA) in the general population compared with central sleep apnea (CSA), more evidence is needed on the long-term clinical impact of and optimal treatment strategies for CSA.

Observations: CSA is overrepresented among certain clinical populations, such as those with heart failure, stroke, neuromuscular disorders, and opioid use. The clinical concerns with CSA parallel those of OSA. The absence of respiration (apneas and hypopneas due to lack of effort) results in sympathetic surge, compromise of oxygenation and ventilation, sleep fragmentation, and elevation in blood pressure. Symptoms such as excessive daytime sleepiness, morning headaches, witnessed apneas, and nocturnal arrhythmias are shared between the 2 disorders. A systematic clinical approach should be used to identify and treat CSA.

Conclusions: The purpose of this review is to familiarize the primary care community with CSA to aid in the identification and management of this breathing disturbance.

背景:虽然文献表明,与中枢睡眠呼吸暂停(CSA)相比,普通人群中中度至重度阻塞性睡眠呼吸暂停(OSA)的患病率更高,但CSA的长期临床影响和最佳治疗策略还需要更多的证据。观察结果:CSA在某些临床人群中被过度代表,例如心力衰竭、中风、神经肌肉疾病和阿片类药物使用的人群。CSA的临床关注与OSA相似。呼吸缺失(由于缺乏努力而导致呼吸暂停和呼吸不足)导致交感神经激增、氧合和通气受损、睡眠中断和血压升高。这两种疾病都有白天嗜睡、早晨头痛、呼吸暂停和夜间心律失常等症状。应采用系统的临床方法来识别和治疗CSA。结论:本综述的目的是使初级保健社区熟悉CSA,以帮助识别和管理这种呼吸障碍。
{"title":"Central Sleep Apnea in Adults: Diagnosis and Treatment.","authors":"Dara D Regn,&nbsp;Anh H Davis,&nbsp;William D Smith,&nbsp;Catherine J Blasser,&nbsp;Caelan M Ford","doi":"10.12788/fp.0367","DOIUrl":"https://doi.org/10.12788/fp.0367","url":null,"abstract":"<p><strong>Background: </strong>While the literature has demonstrated a higher prevalence of moderate-to-severe obstructive sleep apnea (OSA) in the general population compared with central sleep apnea (CSA), more evidence is needed on the long-term clinical impact of and optimal treatment strategies for CSA.</p><p><strong>Observations: </strong>CSA is overrepresented among certain clinical populations, such as those with heart failure, stroke, neuromuscular disorders, and opioid use. The clinical concerns with CSA parallel those of OSA. The absence of respiration (apneas and hypopneas due to lack of effort) results in sympathetic surge, compromise of oxygenation and ventilation, sleep fragmentation, and elevation in blood pressure. Symptoms such as excessive daytime sleepiness, morning headaches, witnessed apneas, and nocturnal arrhythmias are shared between the 2 disorders. A systematic clinical approach should be used to identify and treat CSA.</p><p><strong>Conclusions: </strong>The purpose of this review is to familiarize the primary care community with CSA to aid in the identification and management of this breathing disturbance.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 3","pages":"78-86"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204934/pdf/fp-40-03-78.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9527775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1